epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

Risk monitor

What could slow our studies down, and where?

The risks across every running study: recruitment, the KRIs and QTLs that watch it, and the regional shocks that can hit it from outside.

Sites waiting too long for a first patient

The earliest warning is usually a site's own screening log, not the news. A site is flagged only when a wait this long would be unusual for its expected rate, so a site that is slow by design is not flagged too early. Today, by recruiting study:

What a week's warning is worth: each day a medicine reaches patients later costs its sponsor about $500,000 to $800,000 in lost sales. The median across medicines (Smith, DiMasi and Getz 2024; D47). The Tufts white paper’s estimate (Smith, DiMasi and Getz, white paper 2024; D47).

What separates sites that recruit from those that do not?

Every open site in the six studies, 367 in all, is compared with what it was expected to recruit, given its type, track record, country and protocol. Pooling sites narrows the range chance allows, so patterns no single site can show become visible.

The kind of site explains little

Patients randomised as a share of those expected, by site profileAll open sites; the bar is where an ordinary group of that size would land. Profiles run from ×0.61 to ×1.01

Show data
Each group: sites, patients randomised against expected, and the range ordinary groups of that size fall in
GroupSitesRandomisedExpectedObserved ÷ expectedOrdinary rangeJudgement
Comprehensive cancer centre262337.8×0.608×0.562 to ×1.529Within normal variation
Academic medical centre28129159.1×0.811×0.627 to ×1.451Within normal variation
Regional teaching hospital98342337.8×1.013×0.766 to ×1.262Within normal variation
Dedicated research centre51232242.0×0.959×0.694 to ×1.357Within normal variation
Community hospital46146145.5×1.004×0.674 to ×1.381Within normal variation
Community specialist practice3473103.6×0.705×0.622 to ×1.455Within normal variation
Site new to research84176217.5×0.809×0.739 to ×1.295Within normal variation

How to read it: each row is a kind of site. ×1 means its sites recruited what sites of their kind are expected to; further left is fewer. The bar is how far an ordinary group of that size strays by chance, so a dot inside its bar is no sign that the kind of site matters.

Source: epiClinical synthetic sites. Expectations already allow for site type and track record, so a profile on ×1 is doing what its kind usually does.

What a site has matters more than what it is

Patients randomised as a share of those expected, sites with each fact (filled) and without (hollow)All open sites; sites with the fact in brackets; the band is where an ordinary group of that size would land

Show data
Patients randomised as a share of those expected, sites with each fact against the rest
FactSites with itWithWithoutOrdinary range
Does not check records against the criteria before inviting patients163×0.547×1.172×0.807 to ×1.211
Screening scans are done at another hospital41×0.609×0.939×0.657 to ×1.405
Half a coordinator or less on this study72×0.36×1.027×0.729 to ×1.308
Two or more competing trials open at the site77×0.369×1.044×0.735 to ×1.301
Relies on referrals, with no formal referral network18×0.346×0.94×0.524 to ×1.611
Two in five patients or more travel over an hour43×0.364×0.974×0.645 to ×1.424
Shares its city with another site in the same study193×0.874×0.916×0.822 to ×1.193

How to read it: each row is something recorded about a site. The filled dot is the sites that have it, the hollow dot the sites that do not; further left is fewer patients than expected. The widest gap: sites that two or more competing trials open at the site recruited ×0.37 of what was expected, against ×1.04 for the rest.

Source: epiClinical synthetic sites and screening logs. The first six facts were built into the synthetic data so that the study pages have causes to find. With real data, this chart is where such links would first show, or fail to. Sharing a city with another site in the same study was not built in: ×0.87 against ×0.92, within normal variation. The evidence says sites compete mainly where the eligible pool is scarce (register S-21).